Patients with tumours that carry the BRAFV600E mutation display a less promising prognosis compared to those with a wild type BRAF, in particular, in melanoma, colorectal cancer, and thyroid cancer [19,20,21]. This evidence concerns the gene BRAF and neoplasm.